Stock Analysis on Net

Becton, Dickinson & Co. (NYSE:BDX)

This company has been moved to the archive! The financial data has not been updated since May 5, 2022.

Common Stock Valuation Ratios (Price Multiples)
Quarterly Data

Microsoft Excel

Historical Valuation Ratios (Summary)

Becton, Dickinson & Co., historical price multiples (quarterly data)

Microsoft Excel
Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015
Price to earnings (P/E) 40.44 45.97 34.68 37.43 42.70 49.11 86.01 95.62 75.45 90.00 65.09 83.38 66.87 72.88 408.36 105.60 206.04 49.63 59.56 30.05 28.94 36.65
Price to operating profit (P/OP) 28.57 32.47 24.81 27.29 30.61 33.30 44.46 56.20 43.34 49.82 40.02 29.43 29.40 30.27 43.37 47.87 95.72 67.53 34.59 40.06 21.15 20.05 25.02
Price to sales (P/S) 3.69 3.87 3.43 3.51 3.71 4.07 3.85 4.45 4.00 3.94 4.07 3.82 3.64 3.82 4.06 4.45 4.49 4.94 4.23 3.72 3.21 3.05 2.87
Price to book value (P/BV) 3.02 3.19 2.93 2.89 2.82 3.00 2.78 3.13 3.32 3.23 3.34 3.04 2.91 3.05 3.09 3.07 2.87 2.85 3.95 3.60 4.96 4.99 4.69 4.55 4.56 3.97

Based on: 10-Q (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-K (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-K (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-K (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-K (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-K (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-K (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-Q (reporting date: 2015-12-31).

Valuation ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. Becton, Dickinson & Co. P/E ratio increased from Q4 2021 to Q1 2022 but then slightly decreased from Q1 2022 to Q2 2022.
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. Becton, Dickinson & Co. P/OP ratio increased from Q4 2021 to Q1 2022 but then slightly decreased from Q1 2022 to Q2 2022 not reaching Q4 2021 level.
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Becton, Dickinson & Co. P/S ratio increased from Q4 2021 to Q1 2022 but then slightly decreased from Q1 2022 to Q2 2022.
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. Becton, Dickinson & Co. P/BV ratio increased from Q4 2021 to Q1 2022 but then slightly decreased from Q1 2022 to Q2 2022 not reaching Q4 2021 level.

Price to Earnings (P/E)

Becton, Dickinson & Co., historical P/E calculation (quarterly data)

Microsoft Excel
Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015
No. shares of common stock outstanding1 285,064,629 284,771,077 284,023,582 287,190,180 290,818,504 290,559,991 290,031,363 289,868,551 271,776,378 271,173,148 270,459,892 269,954,141 269,731,903 269,063,379 268,257,940 267,563,574 267,201,840 266,242,472 227,978,328 227,564,969 213,305,385 212,825,085 212,319,588 212,925,842 212,202,004 211,816,526
Selected Financial Data (US$)
Net income (loss) applicable to common shareholders (in millions) 431 655 242 502 277 981 105 277 145 240 125 413 (18) 562 (173) 556 (50) (174) 289 (165) 344 562 19 390 338 229
Earnings per share (EPS)2 6.42 5.89 7.05 6.49 5.64 5.19 2.64 2.72 3.40 2.80 4.00 2.90 3.44 3.33 0.59 2.32 -0.37 1.10 4.52 3.34 6.16 6.15 4.60 0.00 0.00 0.00
Share price1, 3 259.64 270.58 244.46 243.08 240.81 254.89 227.47 259.61 256.25 252.25 260.40 242.14 229.80 242.41 242.04 245.10 227.13 227.52 224.23 198.90 185.28 177.97 168.48 171.53 164.84 135.25
Valuation Ratio
P/E ratio4 40.44 45.97 34.68 37.43 42.70 49.11 86.01 95.62 75.45 90.00 65.09 83.38 66.87 72.88 408.36 105.60 206.04 49.63 59.56 30.05 28.94 36.65
Benchmarks
P/E Ratio, Competitors5
Abbott Laboratories 22.24 25.48 29.13 31.42 33.80 36.79 48.49 58.45 58.36 45.61 41.83
Cigna Group 15.60 15.72 13.43 8.43 8.60 10.62 8.71 14.60 12.08 13.82 13.26
CVS Health Corp. 16.30 16.49 17.39 16.78 14.94 14.44 12.88 10.69 10.20 10.94 14.15
Danaher Corp. 32.73 32.15 29.94 38.81 37.87 39.26 44.49 46.61 41.91 35.88 38.34
Elevance Health Inc. 18.07 20.46 18.13 18.65 22.10 19.99 15.87 14.35 11.97 14.80 15.96
Humana Inc. 19.26 18.48 18.34 22.09 22.82 15.20 14.48 13.49 15.26 19.09 18.10
Intuitive Surgical Inc. 52.74 55.10 59.94 71.86 69.15 89.95 87.47 82.17 70.73 44.27 48.72
Medtronic PLC 30.66 46.71 46.56 55.13 42.80 32.34 26.30 25.38 31.86 32.75 28.78 25.11 57.38 41.16 37.80
UnitedHealth Group Inc. 27.70 27.29 26.03 27.92 27.41 23.06 20.54 17.70 16.88 19.91 20.48

Based on: 10-Q (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-K (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-K (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-K (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-K (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-K (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-K (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-Q (reporting date: 2015-12-31).

1 Data adjusted for splits and stock dividends.

2 Q2 2022 Calculation
EPS = (Net income (loss) applicable to common shareholdersQ2 2022 + Net income (loss) applicable to common shareholdersQ1 2022 + Net income (loss) applicable to common shareholdersQ4 2021 + Net income (loss) applicable to common shareholdersQ3 2021) ÷ No. shares of common stock outstanding
= (431,000,000 + 655,000,000 + 242,000,000 + 502,000,000) ÷ 285,064,629 = 6.42

3 Closing price as at the filing date of Becton, Dickinson & Co. Quarterly or Annual Report.

4 Q2 2022 Calculation
P/E ratio = Share price ÷ EPS
= 259.64 ÷ 6.42 = 40.44

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. Becton, Dickinson & Co. P/E ratio increased from Q4 2021 to Q1 2022 but then slightly decreased from Q1 2022 to Q2 2022.

Price to Operating Profit (P/OP)

Becton, Dickinson & Co., historical P/OP calculation (quarterly data)

Microsoft Excel
Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015
No. shares of common stock outstanding1 285,064,629 284,771,077 284,023,582 287,190,180 290,818,504 290,559,991 290,031,363 289,868,551 271,776,378 271,173,148 270,459,892 269,954,141 269,731,903 269,063,379 268,257,940 267,563,574 267,201,840 266,242,472 227,978,328 227,564,969 213,305,385 212,825,085 212,319,588 212,925,842 212,202,004 211,816,526
Selected Financial Data (US$)
Operating income (loss) (in millions) 652 815 496 628 434 1,241 255 358 370 501 110 626 136 888 571 513 183 230 444 (223) 446 811 96 516 466 352
Operating profit per share2 9.09 8.33 9.85 8.91 7.87 7.65 5.12 4.62 5.91 5.06 6.51 8.23 7.82 8.01 5.58 5.12 2.37 3.37 6.48 4.97 8.76 8.88 6.74 0.00 0.00 0.00
Share price1, 3 259.64 270.58 244.46 243.08 240.81 254.89 227.47 259.61 256.25 252.25 260.40 242.14 229.80 242.41 242.04 245.10 227.13 227.52 224.23 198.90 185.28 177.97 168.48 171.53 164.84 135.25
Valuation Ratio
P/OP ratio4 28.57 32.47 24.81 27.29 30.61 33.30 44.46 56.20 43.34 49.82 40.02 29.43 29.40 30.27 43.37 47.87 95.72 67.53 34.59 40.06 21.15 20.05 25.02
Benchmarks
P/OP Ratio, Competitors5
Abbott Laboratories 18.63 21.33 24.45 26.84 29.01 31.39 40.69 45.82 45.19 35.87 34.03
Cigna Group 10.20 10.40 9.08 9.12 9.28 11.13 9.03 9.24 7.58 8.59 8.38
CVS Health Corp. 9.97 10.06 10.43 9.43 7.87 7.61 6.65 5.89 5.98 6.19 7.83
Danaher Corp. 25.91 26.48 25.14 32.12 30.83 32.62 36.91 46.28 43.09 35.22 34.47
Elevance Health Inc. 14.72 17.53 15.70 15.81 19.93 15.79 12.10 10.93 9.03 11.95 13.55
Humana Inc. 18.96 17.45 17.08 21.55 14.39 11.02 9.78 9.84 11.28 14.59 15.35
Intuitive Surgical Inc. 44.54 49.98 56.11 67.95 69.51 89.18 88.37 83.88 71.30 43.68 48.89
Medtronic PLC 27.20 38.83 37.44 49.88 42.55 35.86 26.29 21.01 23.52 22.21 21.26 19.74 21.13 20.04 17.64
UnitedHealth Group Inc. 19.96 19.69 18.77 19.63 19.05 16.12 14.12 12.35 11.85 13.80 14.40

Based on: 10-Q (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-K (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-K (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-K (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-K (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-K (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-K (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-Q (reporting date: 2015-12-31).

1 Data adjusted for splits and stock dividends.

2 Q2 2022 Calculation
Operating profit per share = (Operating income (loss)Q2 2022 + Operating income (loss)Q1 2022 + Operating income (loss)Q4 2021 + Operating income (loss)Q3 2021) ÷ No. shares of common stock outstanding
= (652,000,000 + 815,000,000 + 496,000,000 + 628,000,000) ÷ 285,064,629 = 9.09

3 Closing price as at the filing date of Becton, Dickinson & Co. Quarterly or Annual Report.

4 Q2 2022 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 259.64 ÷ 9.09 = 28.57

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. Becton, Dickinson & Co. P/OP ratio increased from Q4 2021 to Q1 2022 but then slightly decreased from Q1 2022 to Q2 2022 not reaching Q4 2021 level.

Price to Sales (P/S)

Becton, Dickinson & Co., historical P/S calculation (quarterly data)

Microsoft Excel
Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015
No. shares of common stock outstanding1 285,064,629 284,771,077 284,023,582 287,190,180 290,818,504 290,559,991 290,031,363 289,868,551 271,776,378 271,173,148 270,459,892 269,954,141 269,731,903 269,063,379 268,257,940 267,563,574 267,201,840 266,242,472 227,978,328 227,564,969 213,305,385 212,825,085 212,319,588 212,925,842 212,202,004 211,816,526
Selected Financial Data (US$)
Revenues (in millions) 5,011 4,995 5,136 4,890 4,907 5,315 4,784 3,855 4,253 4,225 4,585 4,350 4,195 4,160 4,403 4,278 4,222 3,080 3,167 3,035 2,969 2,922 3,232 3,198 3,067 2,986
Sales per share2 70.27 69.98 71.29 69.28 64.85 62.66 59.02 58.36 64.07 64.00 63.93 63.37 63.16 63.42 59.58 55.12 50.54 46.01 53.04 53.43 57.76 58.35 58.79 0.00 0.00 0.00
Share price1, 3 259.64 270.58 244.46 243.08 240.81 254.89 227.47 259.61 256.25 252.25 260.40 242.14 229.80 242.41 242.04 245.10 227.13 227.52 224.23 198.90 185.28 177.97 168.48 171.53 164.84 135.25
Valuation Ratio
P/S ratio4 3.69 3.87 3.43 3.51 3.71 4.07 3.85 4.45 4.00 3.94 4.07 3.82 3.64 3.82 4.06 4.45 4.49 4.94 4.23 3.72 3.21 3.05 2.87
Benchmarks
P/S Ratio, Competitors5
Abbott Laboratories 4.18 4.42 4.78 5.38 5.36 5.64 6.30 6.13 5.77 5.09 4.83
Cigna Group 0.48 0.48 0.42 0.42 0.42 0.55 0.46 0.50 0.41 0.45 0.44
CVS Health Corp. 0.43 0.44 0.47 0.45 0.39 0.40 0.35 0.32 0.32 0.30 0.37
Danaher Corp. 6.59 6.68 6.37 7.91 7.72 7.27 7.01 8.15 7.48 6.34 6.29
Elevance Health Inc. 0.75 0.89 0.81 0.78 0.73 0.76 0.60 0.61 0.63 0.65 0.74
Humana Inc. 0.68 0.65 0.65 0.73 0.71 0.73 0.64 0.76 0.76 0.74 0.76
Intuitive Surgical Inc. 12.69 15.34 17.89 22.12 21.73 23.19 21.29 20.09 18.44 13.33 15.01
Medtronic PLC 4.54 5.74 5.57 5.71 5.43 5.11 4.36 4.34 4.82 4.72 4.36 4.04 4.27 4.35 3.92
UnitedHealth Group Inc. 1.66 1.61 1.58 1.55 1.47 1.49 1.24 1.18 1.17 1.12 1.18

Based on: 10-Q (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-K (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-K (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-K (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-K (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-K (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-K (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-Q (reporting date: 2015-12-31).

1 Data adjusted for splits and stock dividends.

2 Q2 2022 Calculation
Sales per share = (RevenuesQ2 2022 + RevenuesQ1 2022 + RevenuesQ4 2021 + RevenuesQ3 2021) ÷ No. shares of common stock outstanding
= (5,011,000,000 + 4,995,000,000 + 5,136,000,000 + 4,890,000,000) ÷ 285,064,629 = 70.27

3 Closing price as at the filing date of Becton, Dickinson & Co. Quarterly or Annual Report.

4 Q2 2022 Calculation
P/S ratio = Share price ÷ Sales per share
= 259.64 ÷ 70.27 = 3.69

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Becton, Dickinson & Co. P/S ratio increased from Q4 2021 to Q1 2022 but then slightly decreased from Q1 2022 to Q2 2022.

Price to Book Value (P/BV)

Becton, Dickinson & Co., historical P/BV calculation (quarterly data)

Microsoft Excel
Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015
No. shares of common stock outstanding1 285,064,629 284,771,077 284,023,582 287,190,180 290,818,504 290,559,991 290,031,363 289,868,551 271,776,378 271,173,148 270,459,892 269,954,141 269,731,903 269,063,379 268,257,940 267,563,574 267,201,840 266,242,472 227,978,328 227,564,969 213,305,385 212,825,085 212,319,588 212,925,842 212,202,004 211,816,526
Selected Financial Data (US$)
Shareholders’ equity (in millions) 24,525 24,160 23,677 24,135 24,826 24,663 23,765 24,022 20,951 21,202 21,081 21,497 21,310 21,403 20,994 21,358 21,152 21,247 12,948 12,587 7,963 7,583 7,633 8,033 7,666 7,223
Book value per share (BVPS)2 86.03 84.84 83.36 84.04 85.37 84.88 81.94 82.87 77.09 78.19 77.95 79.63 79.00 79.55 78.26 79.82 79.16 79.80 56.79 55.31 37.33 35.63 35.95 37.73 36.13 34.10
Share price1, 3 259.64 270.58 244.46 243.08 240.81 254.89 227.47 259.61 256.25 252.25 260.40 242.14 229.80 242.41 242.04 245.10 227.13 227.52 224.23 198.90 185.28 177.97 168.48 171.53 164.84 135.25
Valuation Ratio
P/BV ratio4 3.02 3.19 2.93 2.89 2.82 3.00 2.78 3.13 3.32 3.23 3.34 3.04 2.91 3.05 3.09 3.07 2.87 2.85 3.95 3.60 4.96 4.99 4.69 4.55 4.56 3.97
Benchmarks
P/BV Ratio, Competitors5
Abbott Laboratories 5.21 5.56 5.75 6.61 6.38 6.27 6.65 6.30 5.94 5.40 4.96 4.65 4.86 4.49
Cigna Group 1.86 1.84 1.53 1.49 1.44 1.86 1.46 1.61 1.34 1.51 1.49 1.49 1.44 1.42
CVS Health Corp. 1.77 1.79 1.83 1.71 1.47 1.51 1.33 1.24 1.24 1.21 1.47 1.47 1.23 1.25
Danaher Corp. 4.36 4.36 4.16 5.11 4.82 4.46 3.93 4.38 3.90 3.68 3.72 3.02 3.19 2.88
Elevance Health Inc. 3.08 3.55 3.07 2.88 2.67 2.78 2.19 2.10 2.06 2.23 2.42 2.13 2.40 2.15
Humana Inc. 3.91 3.66 3.34 3.63 3.82 3.99 3.55 3.55 3.71 4.04 4.07 3.48 3.38 3.07
Intuitive Surgical Inc. 6.29 7.48 8.59 10.64 10.35 10.40 9.53 9.35 9.19 7.22 8.13 8.43 8.49 8.68
Medtronic PLC 2.77 3.52 3.26 3.14 3.02 2.84 2.48 2.60 2.94 2.87 2.66 2.48 2.62 2.59 2.31 2.11 2.10 2.14
UnitedHealth Group Inc. 6.94 6.54 6.27 6.13 5.76 5.86 4.83 4.54 4.53 4.81 4.92 4.32 4.40 4.37

Based on: 10-Q (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-K (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-K (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-K (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-K (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-K (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-K (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-Q (reporting date: 2015-12-31).

1 Data adjusted for splits and stock dividends.

2 Q2 2022 Calculation
BVPS = Shareholders’ equity ÷ No. shares of common stock outstanding
= 24,525,000,000 ÷ 285,064,629 = 86.03

3 Closing price as at the filing date of Becton, Dickinson & Co. Quarterly or Annual Report.

4 Q2 2022 Calculation
P/BV ratio = Share price ÷ BVPS
= 259.64 ÷ 86.03 = 3.02

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. Becton, Dickinson & Co. P/BV ratio increased from Q4 2021 to Q1 2022 but then slightly decreased from Q1 2022 to Q2 2022 not reaching Q4 2021 level.